Antitumor effects of cytosine deaminase and thymidine kinase fusion suicide gene under the control of mdr1 promoter in mdr1 positive leukemia cells

References

• Niculescu Duvaz I, Spooner R, Marais R, Springerr C J. Gene-directed enzyme prodrug therapy. Bioconjug Chem 1998; 9: 4–22
   PubMed Web of Science ®Google Scholar
• Springer C J, Niculescu Duvaz I. Prodrug-activating systems in suicide gene therapy. J Clin Invest 2000; 105: 1161–1167
   PubMed Web of Science ®Google Scholar
• Chang J W, Lee H, Kim E, Lee Y, Chung S S, Kim J H. Combined antitumor effects of an adenoviral cytosine deaminase/thymidine kinase fusion gene in rat C6 glioma. Neurosurgery 2000; 47: 931–939
   PubMed Web of Science ®Google Scholar
• Desaknai S, Lumniczky K, Esik O, Hamada H, Safrany G. Local tumour irradiation enhances the anti-tumour effect of a double-suicide gene therapy system in a murine glioma model. J Gene Med 2003; 5: 377–385
   PubMed Web of Science ®Google Scholar
• Ikegami S, Tadakuma T, Ono T, Suzuki S, Yoshimura I, Asano T, et al. Treatment efficiency of a suicide gene therapy using prostate-specific membrane antigen promoter/enhancer in a castrated mouse model of prostate cancer. Cancer Sci 2004; 95: 367–370
   PubMed Web of Science ®Google Scholar
• Song J S, Kim H P, Yoon W S, Lee K W, Kim M H, Kim K T, et al. Adenovirus-mediated suicide gene therapy using the human telomerase catalyticsubunit (hTERT) gene promoter induced apoptosis of ovarian cancer cell line. Biosci Biotechnol Biochem 2003; 67: 2344–2350
   PubMed Web of Science ®Google Scholar
• Shen L Z, Wu W X, Xu D H, Zheng Z C, Liu X Y, Ding Q, et al. Specific CEA-producing colorectal carcinoma cell killing with recombinant adenoviral vector containing cytosine deaminase gene. World J Gastroenterol 2002; 8: 270–275
   PubMed Web of Science ®Google Scholar
• Yu L, Ugai S, Wang J, Namba M, Kadomatsu K, Muramatsu T, et al. Cell growth- and P53-dependent transcriptional activity of the midkine promoter confers suicide gene expression in tumor cells. Oncol Rep 2003; 10: 1301–1305
   PubMed Web of Science ®Google Scholar
• Hirano T, Kaneko S, Kaneda Y, Saito I, Tamaoki T, Furuyama J, et al. HVJ-liposome mediated transfection of HSV-tk gene driven by AFP promoter inhibits hepatic tumor growth of hepatocellular carcinoma in SCID mice. Gene Therapy 2001; 8: 80–83
   PubMed Web of Science ®Google Scholar
• Nooter K, Sonneveld P. Clinical relevance of P-glycoprotein expression in haematological malignancies. Leuk Res 1994; 18: 233–243
   PubMed Web of Science ®Google Scholar
• Leith C P, Kopecky K J, Chen I M, Eijdems L, Slovak M L, McConnell T S, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/p-glycoprotein, MRP1 and LRP in acute myeloid leukemia. A southwest oncology group study. Blood 1999; 94: 1086–1099
   PubMed Web of Science ®Google Scholar
• Damiani D, Michelutti A, Michieli M, Masolini P, Stocchi R, Geromin A, et al. P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukemia. Br J Haematol 2002; 116: 519–527
   PubMed Web of Science ®Google Scholar
• Arceci R J. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993; 81: 2215–2222
   PubMed Web of Science ®Google Scholar
• Gottesman M M, Fojo T, Bates S E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48–58
   PubMed Web of Science ®Google Scholar
• Labialle S, Gayet L, Marthinet E, Rigal D, Baggetto L G. Transcriptional regulators of the human multidrug resistance 1 gene: recent views. Biochem Pharmacol 2002; 64: 943–948
   PubMed Web of Science ®Google Scholar
• Vilaboa N E, Galan A, Troyano A, de Blas E, Aller P. Regulation multidrug resistance 1(MDR1)/P-glycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1). J Biol Chem 2000; 275: 24970–24976
   PubMed Web of Science ®Google Scholar
• Comerford K M, Wallace T J, Karhausen J, Louis N A, Montalto M C, Colgan S P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002; 62: 3387–3394
   PubMed Web of Science ®Google Scholar
• Yang J M, Vassil A D, Hait W N. Activation of phospholipase C induces the expression of the multidrug resistance (MDR1) gene through the Raf-MAPK pathway. Mol Pharmacol 2001; 60: 674–680
   PubMed Web of Science ®Google Scholar
• Raguz S, Tambur De Bella M, Tripuraneni G, Slade M J, Higgins C F, Coombes C R, et al. Activation of the MDR1 upstream promoter in breast carcinoma as a surrogate for metastatic invasion. Clin Cancer Res 2004; 10: 2776–2783
   PubMed Web of Science ®Google Scholar
• Ogretmen B, Safa A R. Identification and characterization of the MDR1 promoter-enhancing factor 1(MEF1) in the multidrug resistant HL60/VCR human acute myeloid leukemia cell line. Biochemistry 2000; 39: 194–204
   PubMed Web of Science ®Google Scholar
• Walther W, Stein U, Schlag P M. Use of the human MDR1 promoter for heat-inducible expression of therapeutic genes. Int J Cancer 2002; 98: 291–296
   PubMed Web of Science ®Google Scholar
• Walther W, Stein U, Fichtner I, Alexander M, Shoemaker R H, Schlag P M. Mdr1 promoter-driven tumor necrosis factor-alpha expression for a chemotherapy-controllable combined in vivo gene therapy and chemotherapy of tumors. Cancer Gene Ther 2000; 7: 893–900
   PubMed Web of Science ®Google Scholar
• Uckert W, Kammertons T, Haack K, Qin Z, Gebert J, Schendel D J, et al. Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. Hum Gene Ther 1998; 9: 855–865
   PubMed Web of Science ®Google Scholar
• Carrio M, Visa J, Cascante A, Estivill X, Fillat C. Intratumoral activation of cyclophosphamide by retroviral transfer of the cytochrome P450 2B1 in a pancreatic tumor model. Combination with the HSV-tk/GCV system. J Gene Med 2002; 4: 141–149
   PubMed Web of Science ®Google Scholar
• Yoshimura I, Suzuki S, Tadakuma T, Hayakawa M. Suicide gene therapy on LNCaP human prostate cancer cells. Int J Urol 2001; 8: S5–S8
   Web of Science ®Google Scholar
• Kieback D G, Fischer D C, Engehausen D G, Sauerbrei W, Oehler M K, Tong X W, et al. Intraperitoneal adenovirus-mediated suicide gene therapy in combination with either topotecan or paclitaxel in nude mice with human ovarian cancer. Cancer Gene Ther 2002; 9: 478–481
   PubMed Web of Science ®Google Scholar